TransCode Therapeutics’ (RNAZ) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research report released on Tuesday, Benzinga reports.

TransCode Therapeutics Stock Down 3.4 %

Shares of TransCode Therapeutics stock opened at $0.49 on Tuesday. The stock’s fifty day moving average is $0.66 and its two-hundred day moving average is $6.11. The company has a market capitalization of $2.82 million, a PE ratio of 0.00 and a beta of -0.35. TransCode Therapeutics has a 52 week low of $0.47 and a 52 week high of $356.00.

Hedge Funds Weigh In On TransCode Therapeutics

Hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC bought a new position in shares of TransCode Therapeutics during the 4th quarter worth $46,000. UBS Group AG bought a new position in shares of TransCode Therapeutics during the 3rd quarter worth $74,000. Sabby Management LLC grew its position in shares of TransCode Therapeutics by 32.8% during the 3rd quarter. Sabby Management LLC now owns 250,309 shares of the company’s stock worth $126,000 after buying an additional 61,872 shares in the last quarter. Worth Venture Partners LLC grew its position in shares of TransCode Therapeutics by 9.7% during the 1st quarter. Worth Venture Partners LLC now owns 324,157 shares of the company’s stock worth $934,000 after buying an additional 28,617 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of TransCode Therapeutics during the 2nd quarter worth $25,000.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.